Modification of amyloid-β(1-40) by a protease inhibitor creates risk of error in mass spectrometric quantitation of amyloid-β(1-42)

被引:5
|
作者
Conboy, James J. [1 ]
Wood, Kathleen G. [1 ]
Lame, Mary E. [1 ]
Durham, Robert A. [1 ]
Geoghegan, Kieran F. [1 ]
机构
[1] Pfizer Inc, Global Res & Dev, Groton, CT 06340 USA
关键词
Mass spectrometry;
D O I
10.1016/j.ab.2008.07.033
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Matrix-assisted laser desorption mass spectrometry successfully analyzes mixed populations of amyloid-beta (A beta) peptides, providing a profile in which changes caused by drug action are directly observed. A spectrum of A beta immunocaptured from guinea pig brain included a novel component with monoisotopic [M+H](+) at 4511.22, close to the monoisotopic value of [M+H](+) for A beta(1-42) of 4512.27 and overlapping and interfering with the authentic A beta(1-42) peak. Hypothesis and experiment led to the conclusion that modification of A13(1-40) by the protease inhibitor aminoethylbenzenesulfonyl fluoride generates a product with monoisotopic [M+H](+) at 4511.19, and that this accounts for the interfering peak. (C) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:147 / 149
页数:3
相关论文
共 50 条
  • [1] Prevention of Amyloid-β Fibril Formation Using Antibodies Against the C-terminal Region of Amyloid-β1-40 and Amyloid-β1-42
    Montanes, Maria
    Casabona, Diego
    Sarasa, Leticia
    Pesini, Pedro
    Sarasa, Manuel
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2013, 34 (01) : 133 - 137
  • [2] Comparison of Alzheimer's amyloid-β(1-40) and amyloid-β(1-42) fibrils as determined by solution NMR spectroscopy
    Olofsson, A.
    Lindhagen-Persson, M.
    Sauer-Eriksson, A. E.
    Ohman, A.
    [J]. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2006, 13 : 50 - 50
  • [3] Amyloid-β1-40 Inhibits Amyloid-β1-42 Induced Activation of Cytoplasmic Phospholipase A2 and Synapse Degeneration
    Bate, Clive
    Williams, Alun
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2010, 21 (03) : 985 - 993
  • [4] A protocol for quantitative analysis of murine and human amyloid-β1-40 and 1-42
    Illouz, Tomer
    Madar, Ravit
    Griffioen, Kathleen
    Okun, Eitan
    [J]. JOURNAL OF NEUROSCIENCE METHODS, 2017, 291 : 28 - 35
  • [5] Stability of Plasma Amyloid-β 1-40, Amyloid-β 1-42, and Total Tau Protein over Repeated Freeze/Thaw Cycles
    Liu, Huei-Chun
    Chiu, Ming-Jang
    Lin, Chin-Hsien
    Yang, Shieh-Yueh
    [J]. DEMENTIA AND GERIATRIC COGNITIVE DISORDERS EXTRA, 2020, 10 (01) : 46 - 55
  • [6] Discrete Molecular Dynamics simulations on hexameric amyloid-β (1-40) and (1-42) models
    Yun, Sijung
    Guy, H. Robert
    [J]. BIOPHYSICAL JOURNAL, 2009, 96 (03) : 219A - 219A
  • [7] Amide solvent protection analysis demonstrates that amyloid-β(1-40) and amyloid-β(1-42) form different fibrillar structures under identical conditions
    Olofsson, Anders
    Lindhagen-Persson, Malin
    Sauer-Eriksson, A. Elisabeth
    Ohman, Anders
    [J]. BIOCHEMICAL JOURNAL, 2007, 404 (01) : 63 - 70
  • [8] Structures and free energy landscapes of aqueous zinc(II)-bound amyloid-β(1-40) and zinc(II)-bound amyloid-β(1-42) with dynamics
    Wise-Scira, Olivia
    Xu, Liang
    Perry, George
    Coskuner, Orkid
    [J]. JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY, 2012, 17 (06): : 927 - 938
  • [9] A method for the detection of amyloid-β1-40, amyloid-β1-42 and amyloid-β oligomers in blood using magnetic beads in combination with flow cytometry and its application in the diagnostics of Alzheimer's disease
    Santos, Alexander Navarrete
    Simm, Andreas
    Holthoff, Vjera
    Boehm, Gerald
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2008, 14 (02) : 127 - 131
  • [10] An automated clinical mass spectrometric method for identification and quantification of variant and wild-type amyloid-β 1-40 and 1-42 peptides in CSF
    DeMarco, Mari L.
    Quyen Nguyen
    Fok, Alice
    Hsiung, Ging-Yuek Robin
    van der Gugten, J. Grace
    [J]. ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING, 2020, 12 (01)